Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00876382 · ClinicalTrials.gov registry record
Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell Carcinoma
A clinical trial, sponsored by SCRI Development Innovations.
- Completed
- Registry status
- 47
- Enrollment target
NCT00876382 is a clinical trial that has completed, run by SCRI Development Innovations. The registered enrollment target is 47 participants.
The verdict
NCT00876382 has completed, sponsored by SCRI Development Innovations.
- COMPLETED
- Registry status
- 47 participants
- Enrollment target
Study Summary
A retrospective medical record abstraction study of at least 200 advanced renal cell carcinoma patients treated in the following settings: * Patients with advanced renal cell carcinoma treated with Sorafenib (Nexavar) as second-line therapy after Sunitinib (Sutent) or Bevacizumab (Avastin) for first-line therapy (about 100 patients) * Patients with advanced renal cell carcinoma treated with Sorafenib (Nexavar) as first-line therapy followed by Sunitinib (Sutent) as second-line therapy (about 100 patients)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2009-05 |
| Est. Completion | 2011-08 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00876382
The ClinicalTrials.gov registry entry for NCT00876382 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 47 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SCRI Development Innovations, which has 146 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00876382 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00876382 about?
NCT00876382 is a clinical study titled "Community Oncology Setting Disease Outcomes of Sorafenib (Nexavar) Use in Advanced Renal Cell Carcinoma". A retrospective medical record abstraction study of at least 200 advanced renal cell carcinoma patients treated in the following settings: * Patients with advanced renal cell carcinoma treated with Sorafenib (Nexavar) as second-line therapy after Sunitinib (Sutent) or Bevacizumab (Avastin) for firs...
What is the current status of trial NCT00876382?
This trial is currently completed. The enrollment target is 47 participants. The study started on 2009-05. Estimated completion is 2011-08.
Who is sponsoring clinical trial NCT00876382?
This trial is sponsored by SCRI Development Innovations, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.